Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study.

Publication Year: 2024

DOI:
10.1186/s12933-024-02164-8

PMCID:
PMC10894470

PMID:
38402400

Journal Information

Full Title: Cardiovasc Diabetol

Abbreviation: Cardiovasc Diabetol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Vascular Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateEach participating center obtained ethical approval, and all participants provided written informed consent. Competing interestsDr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have nothing to disclose. Competing interests Dr. Levy is the author of a patent owned by his university regarding use of haptoglobin genotype to predict susceptibility to cardiovascular disease in individuals with diabetes. All other authors have nothing to disclose."

Evidence found in paper:

"Funding L.EC. was funded by a CIHR Project grant (PJT173471) for this work. M.A.E received funding from the NIH (DK057136)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025